Oxetorone Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414665

CAS#: 26020-55-3 (free base)

Description: Oxetorone Free Base is used in the treatment of migraine.

Chemical Structure

No image available
Oxetorone Free Base
CAS# 26020-55-3 (free base)

Theoretical Analysis

MedKoo Cat#: 414665
Name: Oxetorone Free Base
CAS#: 26020-55-3 (free base)
Chemical Formula: C21H21NO2
Exact Mass: 319.1572
Molecular Weight: 319.4
Elemental Analysis: C, 78.97; H, 6.63; N, 4.39; O, 10.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 26020-55-3 (free base); 34522-46-8 (fumarate)  

Synonym: Oxetorone Free Base; Oxetorona; Oxetoronum

IUPAC/Chemical Name: 3-(12H-Benzofuro(3,2-c)(1)benzoxepin-6-yliden)-N,N-dimethylpropylamin


InChi Code: InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3/b17-10+


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 319.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Macaigne G, Boivin JF, Chayette C, Cheaib S, Deplus R. Colite lymphocytaire associée à la prise d'oxétorone [Oxetorone-associated lymphocytic colitis]. Gastroenterol Clin Biol. 2002 May;26(5):537. French. PMID: 12122372.

2: Deguigne M, Bruneau C, Touré A, Turcant A, Le Roux G. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2017 Feb;55(2):142-146. doi: 10.1080/15563650.2016.1267358. Epub 2016 Dec 14. PMID: 27967233.

3: Pradalier A, Molitor JL, Campinos C. Oxétorone et sueurs profuses [Oxetorone and profuse sweating]. Therapie. 2003 Mar-Apr;58(2):166-7. French. doi: 10.2515/therapie:2003025. PMID: 12942859.

4: Payen C, Patat AM, Pulce C, Descotes J. Intoxication aiguë par oxetorone [Acute poisoning with oxetorone]. Therapie. 2006 Nov-Dec;61(6):548-50. French. doi: 10.2515/therapie:2006081. PMID: 17348615.

5: Pradalier A. Hyperprolactinaemia and depression induced by oxetorone. Cephalalgia. 1996 Dec;16(8):560-1. doi: 10.1046/j.1468-2982.1996.1608560.x. PMID: 8980859.

6: Fathallah N, Chatti S, Azouz MM. Colite lymphocytaire associée à la prise d'oxétorone [Lymphocytic colitis associated with oxetorone consumption]. Gastroenterol Clin Biol. 2010 Feb;34(2):154-5. French. doi: 10.1016/j.gcb.2009.12.001. Epub 2010 Jan 21. PMID: 20096517.

7: Galerneau V, Petit J, Deghmani M, Leroy J, Droy JM, Leroy A, Oksenhendler G, Winckler C. Severe self-poisoning with oxetorone: report of one case. J Toxicol Clin Toxicol. 1990;28(1):111-6. doi: 10.3109/15563659008993482. PMID: 2381017.

8: Roos C. Migraine : données épidémiologiques, cliniques et thérapeutiques [Migraine epidemiological, clinical and therapeutic data]. Biol Aujourdhui. 2019;213(1-2):35-41. French. doi: 10.1051/jbio/2019019. Epub 2019 Jul 5. PMID: 31274101.

9: Barchewitz G, Vernant C, Mazue G, Binon F, Cier A, Tuchmann Duplessis H. Oxetorone-induced hyperprogesteronemia and the development of uterine decidual lesions in rats. Arzneimittelforschung. 1984;34(9):1007-10. PMID: 6542368.

10: de Coster J. Etude de l'oxétorone dans les céphalées migraineuses [Oxetorone in the treatment of migrainous cephalalgia (author's transl)]. Schweiz Rundsch Med Prax. 1976 Jul 13;65(28):879-82. French. PMID: 1005299.